Literature DB >> 8960538

Re: Caplan et al. IJROBP 29:1183-1186; 1994, and Bentzen et al. IJROBP 32:1531-1534; 1995.

R Chappell.   

Abstract

Mesh：

Year:  1996        PMID： 8960538     DOI： 10.1016/s0360-3016(97)89873-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  3 in total

1.  The use and interpretation of competing risks regression models.

Authors:  James J Dignam; Qiang Zhang; Masha Kocherginsky
Journal:  Clin Cancer Res       Date:  2012-01-26       Impact factor: 12.531

2.  Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.

Authors:  Koen van Besien; Rangesh Kunavakkam; Gaby Rondon; Marcos De Lima; Andrew Artz; Betul Oran; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2009-05       Impact factor: 5.742

3.  Choice and interpretation of statistical tests used when competing risks are present.

Authors:  James J Dignam; Maria N Kocherginsky
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.